Q4 2019/20 Initiation

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162140	19/LO/0308	257755	VIVOTM non-invasive mapping of ventricular arrhythmia	Yes	03/07/2019	26	33	59	01/03/2019	05/05/2019	21/04/2019	15/05/2019	31/05/2019	Please Select...	31/05/2019	Please Select...
162141	19/LO/0784	264744	A Pilot Study to exPlOre the exisTence and impact of FRAILTY in patients over the age of 70 undergoing cardiac interventions	Yes	20/08/2019	31	11	42	01/04/2019	09/07/2019	16/07/2019	24/07/2019	09/08/2019	Please Select...	09/08/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162142	19/SC/0050	259683	"Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction (PiCSO-AMI-I)"	Yes	23/09/2019	40	12	52	01/04/2019	02/08/2019	16/07/2019	14/08/2019	11/09/2019	Please Select...	16/09/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162143	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Yes	18/09/2019	8	36	44	15/04/2019	05/08/2019	14/06/2019	01/08/2019	13/08/2019	Please Select...	13/08/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162144	18/LO/0020	226737	A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Undergoing Coronary	Yes	16/03/2020	12	97	109	20/11/2017	28/11/2019	18/03/2018	03/12/2019	10/12/2019	Please Select...	10/12/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162145	19/NW/0540	269907	A Phase 3 study of the long-term safety of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older	Yes - Date Unavailable		37			28/08/2019	12/11/2019	06/11/2019	04/12/2019	19/12/2019	Please Select...	19/12/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162146	19/NW/0506	269510	A Phase 3 study of the efficacy, safety and the body?s effects on a triple combination therapy of VX-445, tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11	Yes - Date Unavailable		31			12/02/2019	04/11/2019	04/11/2019	04/12/2019	05/12/2019	Please Select...	05/12/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162147	19/LO/1318	268820	A study to evaluate the effectiveness and safety of VX 445/Tezacaftor/Ivacaftor in people with Cystic Fibrosis who are heterozygous for the F508del mutation and a gating or residual function mutation	Yes	10/02/2020	40	63	103	19/06/2019	30/10/2019	29/10/2019	13/11/2019	09/12/2019	Please Select...	09/12/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162148	19/YH/0222	252494	"Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People."	Yes	30/10/2019	0	22	22	17/06/2019	08/10/2019	24/07/2019	08/10/2019	08/10/2019	Please Select...	08/10/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162149	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure	Yes	03/09/2019	0	11	11	04/06/2019	23/08/2019	26/07/2019	23/08/2019	23/08/2019	Please Select...	30/08/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162150	19/EM/0267	262581	SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation discharge: a randomised controlled trial evaluating the long-term effects on exercise tolerance and mental wellbeing	Yes	15/11/2019	13	17	30	19/08/2019	16/10/2019	10/10/2019	10/10/2019	29/10/2019	Please Select...	29/10/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162151	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Yes	27/02/2020	35	183	218	13/03/2019	24/07/2019	17/06/2019	27/08/2019	28/08/2019	Please Select...	28/08/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
162152	18/LO/2006	250980	A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications	No		29			28/11/2018	05/09/2019	14/02/2019	24/09/2019	04/10/2019	Please Select...	04/10/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163700	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	12	8	20	19/03/2020	19/03/2020	17/03/2020	13/03/2020	31/03/2020	Please Select...	31/03/2020	Please Select...
163701	18/EM/0365	252018	An open-label extension trial of the long-term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)	Yes	04/06/2019	0	22	22	18/01/2019	13/05/2019	15/01/2019	13/05/2019	13/05/2019	Please Select...	03/06/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163702	19/LO/1167	263830	A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat? inhaler as add-on therapy to	No		129			28/06/2019	19/07/2019	05/11/2019	19/11/2019	25/11/2019	Please Select...	28/11/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163703	18/EM/0406	250403	EURO SHOCK Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in Cardiogenic Shock	No		151			18/03/2019	09/08/2019	04/03/2019	07/01/2020	07/01/2020	Please Select...	15/01/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163704	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	No		160			17/09/2019	17/09/2019	31/10/2019	21/02/2020	24/02/2020	Please Select...	24/02/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163705	19/WA/0277	269743	An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging	Yes	19/02/2020	126	28	154	10/07/2019	18/09/2019	04/11/2019	14/01/2020	22/01/2020	Please Select...	22/01/2020	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163706	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor	Yes	08/01/2020	34	71	105	28/06/2019	25/09/2019	24/09/2019	24/09/2019	29/10/2019	Please Select...	29/10/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163708	19/LO/1317	268821	A Phase 3 study of the long-term safety and efficacy of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older who have one copy of the F508del mutation and one copy of a	Yes	17/04/2020	128	42	170	20/09/2019	30/10/2019	29/10/2019	02/12/2019	06/03/2020	Please Select...	06/03/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163709	18/EE/0390	253601	A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to	No		50			09/12/2019	10/12/2019	25/03/2019	27/01/2020	29/01/2020	Please Select...	29/01/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
163710	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	No		21			31/10/2019	06/01/2020	11/12/2019	07/01/2020	27/01/2020	Please Select...	27/02/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:

Q1 2020/21 Initiation

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167374	19/LO/0784	264744	A Pilot Study to exPlOre the exisTence and impact of FRAILTY in patients over the age of 70 undergoing cardiac interventions	Yes	20/08/2019	31	11	42	01/04/2019	09/07/2019	16/07/2019	24/07/2019	09/08/2019	Please Select...	09/08/2019	Please Select...
167375	19/SC/0050	259683	"Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction (PiCSO-AMI-I)"	Yes	23/09/2019	40	12	52	01/04/2019	02/08/2019	16/07/2019	14/08/2019	11/09/2019	Please Select...	16/09/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167376	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Yes	18/09/2019	8	36	44	15/04/2019	05/08/2019	14/06/2019	01/08/2019	13/08/2019	Please Select...	13/08/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167377	18/LO/0020	226737	A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. Protocol: CLX003-IMP-2-170121	Yes	16/03/2020	12	97	109	20/11/2017	28/11/2019	18/03/2018	03/12/2019	10/12/2019	Please Select...	10/12/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167378	19/NW/0540	269907	A Phase 3 study of the long-term safety of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older	Yes - Date Unavailable		37			28/08/2019	12/11/2019	06/11/2019	04/12/2019	19/12/2019	Please Select...	19/12/2019	Please Select...
167379	19/NW/0506	269510	A Phase 3 study of the efficacy, safety and the body?s effects on a triple combination therapy of VX-445, tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11	Yes - Date Unavailable		31			12/02/2019	04/11/2019	04/11/2019	04/12/2019	05/12/2019	Please Select...	05/12/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167380	19/LO/1318	268820	A study to evaluate the effectiveness and safety of VX 445/Tezacaftor/Ivacaftor in people with Cystic Fibrosis who are heterozygous for the F508del mutation and a gating or residual function mutation	Yes	10/02/2020	40	63	103	19/06/2019	30/10/2019	29/10/2019	13/11/2019	09/12/2019	Please Select...	09/12/2019	Please Select...
167381	19/YH/0222	252494	"Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People."	Yes	30/10/2019	0	22	22	17/06/2019	08/10/2019	24/07/2019	08/10/2019	08/10/2019	Please Select...	08/10/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167382	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care	Yes	03/09/2019	0	11	11	04/06/2019	23/08/2019	26/07/2019	23/08/2019	23/08/2019	Please Select...	30/08/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167383	19/EM/0267	262581	"SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation discharge: a randomised controlled trial evaluating the long-term effects on exercise tolerance and mental wellbeing"	Yes	15/11/2019	13	17	30	19/08/2019	16/10/2019	10/10/2019	10/10/2019	29/10/2019	Please Select...	29/10/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167384	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Yes	27/02/2020	35	183	218	13/03/2019	24/07/2019	17/06/2019	27/08/2019	28/08/2019	Please Select...	28/08/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167385	18/LO/2006	250980	A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications	No		29			28/11/2018	05/09/2019	14/02/2019	24/09/2019	04/10/2019	Please Select...	04/10/2019	NHS Provider
167386	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	12	8	20	19/03/2020	19/03/2020	17/03/2020	13/03/2020	31/03/2020	Please Select...	31/03/2020	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167387	19/LO/1167	263830	A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat? inhaler as add-on therapy to standard of care over 4 weeks in patients with cystic fibrosis	No		129			28/06/2019	19/07/2019	05/11/2019	19/11/2019	25/11/2019	Please Select...	28/11/2019	NHS Provider
167388	18/EM/0406	250403	EURO SHOCK Testing the	No		151			18/03/2019	09/08/2019	04/03/2019	07/01/2020	07/01/2020	Please Select...	15/01/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167389	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	No		160			17/09/2019	17/09/2019	31/10/2019	21/02/2020	24/02/2020	Please Select...	24/02/2020	NHS Provider
167390	19/WA/0277	269743	An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging	Yes	19/02/2020	126	28	154	10/07/2019	18/09/2019	04/11/2019	14/01/2020	22/01/2020	Please Select...	22/01/2020	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167391	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks	Yes	08/01/2020	34	71	105	28/06/2019	25/09/2019	24/09/2019	24/09/2019	29/10/2019	Please Select...	29/10/2019	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167392	19/LO/1317	268821	A Phase 3 study of the long-term safety and efficacy of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older who have one copy of the F508del mutation and one copy of a gating or residual function mutation	Yes	17/04/2020	128	42	170	20/09/2019	30/10/2019	29/10/2019	02/12/2019	06/03/2020	Please Select...	06/03/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167393	18/EE/0390	253601	A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical treatment Chronic	No		50			09/12/2019	10/12/2019	25/03/2019	27/01/2020	29/01/2020	Please Select...	29/01/2020	NHS Provider
167394	18/NI/0145	252483	A phase 1/2a study to assess	No		21			31/10/2019	06/01/2020	11/12/2019	07/01/2020	27/01/2020	Please Select...	27/02/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167401	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	No		14			27/03/2020	31/03/2020	23/07/2018	06/04/2020	14/04/2020	Please Select...	14/04/2020	Neither
167402	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	No		0			14/04/2020	17/04/2020	03/04/2020	17/04/2020	17/04/2020	Please Select...	17/04/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167403	20/NW/0195	1003047	A Phase 3b randomised, placebo-controlled study of the efficacy and safety of a triple combination therapy of elexacaftor (VX-445), tezacaftor and ivacaftor in people with cystic fibrosis aged 6 to 11 with one F508del mutation and one minimal function mutation	No		104			28/02/2020	14/05/2020	14/05/2020	18/05/2020	26/08/2020	Please Select...	27/08/2020	Neither

Q2 2020/21 Initiation

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167404	18/LO/0020	226737	A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery. Protocol: CLX003-IMP-2-170121	Yes	16/03/2020	12	97	109	20/11/2017	28/11/2019	18/03/2018	03/12/2019	10/12/2019	Please Select...	10/12/2019	NHS Provider
167405	19/NW/0540	269907	A Phase 3 study of the long-term safety of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older	Yes - Date Unavailable		37			28/08/2019	12/11/2019	06/11/2019	04/12/2019	19/12/2019	Please Select...	19/12/2019	Please Select...
167406	19/NW/0506	269510	A Phase 3 study of the efficacy, safety and the body?s effects on a triple combination therapy of VX-445, tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11	Yes - Date Unavailable		31			12/02/2019	04/11/2019	04/11/2019	04/12/2019	05/12/2019	Please Select...	05/12/2019	Please Select...
167407	19/LO/1318	268820	A study to evaluate the effectiveness and safety of VX 445/Tezacaftor/Ivacaftor in people with Cystic Fibrosis who are heterozygous for the F508del mutation and a gating or residual function mutation	Yes	10/02/2020	40	63	103	19/06/2019	30/10/2019	29/10/2019	13/11/2019	09/12/2019	Please Select...	09/12/2019	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167408	19/YH/0222	252494	"Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People."	Yes	30/10/2019	0	22	22	17/06/2019	08/10/2019	24/07/2019	08/10/2019	08/10/2019	Please Select...	08/10/2019	Please Select...
167409	19/EM/0267	262581	"SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation discharge: a randomised controlled trial evaluating the long-term effects on exercise tolerance and mental wellbeing"	Yes	15/11/2019	13	17	30	19/08/2019	16/10/2019	10/10/2019	10/10/2019	29/10/2019	Please Select...	29/10/2019	Please Select...
167410	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	12	8	20	19/03/2020	19/03/2020	17/03/2020	13/03/2020	31/03/2020	Please Select...	31/03/2020	Please Select...
167411	19/LO/1317	268821	A Phase 3 study of the long-term safety and efficacy of a triple combination therapy of VX-445, tezacaftor and ivacaftor in people with cystic fibrosis aged 12 and older who have one copy of the F508del mutation and one copy of a gating or residual function mutation	Yes	17/04/2020	128	42	170	20/09/2019	30/10/2019	29/10/2019	02/12/2019	06/03/2020	Please Select...	06/03/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167412	18/EE/0390	253601	A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical treatment Chronic Thromboembolic Pulmonary Hypertension.	No		50			09/12/2019	10/12/2019	25/03/2019	27/01/2020	29/01/2020	Please Select...	29/01/2020	NHS Provider
167413	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC	No		21			31/10/2019	06/01/2020	11/12/2019	07/01/2020	27/01/2020	Please Select...	27/02/2020	Neither
167414	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	No		14			27/03/2020	31/03/2020	23/07/2018	06/04/2020	14/04/2020	Please Select...	14/04/2020	Neither
167415	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	No		0			14/04/2020	17/04/2020	03/04/2020	17/04/2020	17/04/2020	Please Select...	17/04/2020	Neither
167416	20/NW/0195	1003047	A Phase 3b randomised, placebo-controlled study of the efficacy and safety of a triple combination therapy of elexacaftor (VX-445), tezacaftor and ivacaftor in people with cystic fibrosis aged 6 to 11 with one F508del mutation and one minimal function mutation	No		104			28/02/2020	14/05/2020	14/05/2020	18/05/2020	26/08/2020	Please Select...	27/08/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
167417	19/LO/1402	268185	Breathe Plus: Testing the feasibility of a comprehensive geriatric assessment for people with COPD and frailty starting pulmonary rehabilitation	Yes	25/02/2020	69	49	118	23/10/2019	30/10/2019	23/10/2019	07/01/2020	07/01/2020	Please Select...	12/02/2020	Sponsor

Q4 2019/20 Delivery

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46044	18/LO/0503	239042	Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with idiopathic pulmonary fibrosis (IPF) on no background anti-fibrotic (Part 1) and safety and tolerability of BI 1015550 on top of Nintedanib and Pir	Number Agreed	1	1	Date Agreed	18/09/2019	1	23/07/2019	1	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46045	12/SS/0037	87162	The?Effects?of?Inorganic?Nitrite?on?cardiac?and?skeletal?muscle:?Physiology, Pharmacology, and Therapeutic?Potential in patients with Chronic Heart Failure	Number Agreed	16	16	Date Agreed	28/06/2019	18	28/06/2019	18	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46046	17/LO/1088	228921	A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation	Number Agreed	3	3	Date Agreed	24/11/2018	5	24/08/2019	5	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46047	16/LO/0286	188120	The?CELEB?trial:?Comparative?Effectiveness?of?Lung?volume?reduction?surgery?for?Emphysema?and?Bronchoscopic lung?volume?reduction?with?valve?placement	Range Agreed	30	40	Date Agreed	28/08/2019	30	28/08/2019	30	Recruitment Finished
46048	19/NW/0026	249432	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	31/08/2019	3	05/09/2019	3	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46049	18/LO/0295	238305	An Open-label, non-controlled, multicentre, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection - OPTIMA	Number Agreed	1	1	Date Agreed	25/10/2019	2	25/10/2019	2	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46050	16/WS/0223	213242	A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without en	Number Agreed	2	2	Date Agreed	31/10/2019	1	31/10/2019	1	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46051	18/EE/0092	235968	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and	Number Agreed	6	6	Date Agreed	31/07/2019	8	06/12/2019	8	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
46052	18/NI/0178	253727	A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation	Number Agreed	2	2	Date Agreed	30/12/2019	0	10/12/2019	0	Withdrawn By Sponsor
46053	18/LO/0967	230460	Clinical Investigation of the VytronUS Ablation System for Treatment	Number Agreed	15	15	Date Agreed	31/12/2019	6	06/09/2019	6	Withdrawn By Sponsor
47812	17/EE/0517	237814	Evaluation of patient experiences of Inhaled Iloprost using the Breelib nebulizer	Number Agreed	10	10	Date Agreed	15/05/2019	5	15/05/2019	5	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47813	18/NE/0033	239296	Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Recurrent Atrial Fibrillation Following a Failed AF Ablation	Number Agreed	10	10	Date Agreed	01/02/2019	9	18/06/2019	9	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47814	18/EE/0235	248137	A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid plus Long acting ?	Number Agreed	10	10	Date Agreed	24/06/2019	8	24/06/2019	8	Recruitment Finished
47815	17/SC/0607	217496	A randomised, controlled trial of the use of a dedicated ballooned intercostal drain	Number Agreed	5	5	Date Agreed	01/05/2019	12	28/06/2019	12	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47816	18/SW/0115	241436	AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS- IMPALA EXTENSION	Number Agreed	4	4	Date Agreed	21/06/2021	4	25/07/2019	4	Withdrawn By Sponsor

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47817	19/NW/0394	264789	CQAW039B2201: A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years with asthma	Number Agreed	1	1	Date Agreed	30/06/2020	0	16/12/2019	0	Withdrawn By Sponsor

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47818	17/NW/0678	233267	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectas	Number Agreed	3	3	Date Agreed	31/12/2019	0	31/12/2019	0	Withdrawn By Sponsor

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47819	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and	Number Agreed	3	3	Date Agreed	01/03/2020	4	01/03/2020	4	Recruitment Finished

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
47820	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/- intervention on outcomes in patients with non ST-elevation myocardial infarction	Number Agreed	25	25	Date Agreed	30/09/2020	0	19/03/2020	0	Withdrawn By Host

d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial

Q1 2020/21 Delivery

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48419	18/LO/0503	239042	Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with idiopathic pulmonary fibrosis (IPF) on no background anti-fibrotic (Part 1) and safety and tolerability of BI 1015550 on top of Nintedanib and Pir	Number Agreed	1	1	Date Agreed	18/09/2019	1	23/07/2019	1	Recruitment Finished
48420	17/LO/1088	228921	A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation	Number Agreed	3	3	Date Agreed	24/11/2018	5	24/08/2019	5	Recruitment Finished
48421	16/LO/0286	188120	The?CELEB?trial:?Comparative?Effectiveness?of?Lung?volume?reduction?surgery?for?Emphysema?and?Bronchoscopic lung?volume?reduction?with?valve?placement	Range Agreed	30	40	Date Agreed	28/08/2019	30	28/08/2019	30	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48422	19/NW/0026	249432	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	31/08/2019	3	05/09/2019	3	Recruitment Finished
48423	18/LO/0295	238305	An Open-label, non-controlled, multicentre, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection - OPTIMA	Number Agreed	1	1	Date Agreed	25/10/2019	2	25/10/2019	2	Recruitment Finished
48424	16/WS/0223	213242	A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without en	Number Agreed	2	2	Date Agreed	31/10/2019	1	31/10/2019	1	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48425	18/EE/0092	235968	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and	Number Agreed	6	6	Date Agreed	31/07/2019	8	06/12/2019	8	Recruitment Finished
48426	18/NI/0178	253727	A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation	Number Agreed	2	2	Date Agreed	30/12/2019	0	10/12/2019	0	Withdrawn By Sponsor
48427	18/LO/0967	230460	Clinical Investigation of the VytronUS Ablation System for Treatment	Number Agreed	15	15	Date Agreed	31/12/2019	6	06/09/2019	6	Withdrawn By Sponsor
48428	18/SW/0115	241436	AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS- IMPALA EXTENSION	Number Agreed	4	4	Date Agreed	21/06/2021	4	25/07/2019	4	Withdrawn By Sponsor

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48429	19/NW/0394	264789	CQAW039B2201: A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years with asthma	Number Agreed	1	1	Date Agreed	30/06/2020	0	16/12/2019	0	Withdrawn By Sponsor
48430	17/NW/0678	233267	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectas	Number Agreed	3	3	Date Agreed	31/12/2019	0	31/12/2019	0	Withdrawn By Sponsor
48431	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and	Number Agreed	3	3	Date Agreed	01/03/2020	4	01/03/2020	4	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48432	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/- intervention on outcomes in patients with non ST-elevation myocardial infarction	Number Agreed	25	25	Date Agreed	30/09/2020	0	19/03/2020	0	Withdrawn By Host
48437	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	31/01/2020	3	31/03/2020	3	Recruitment Finished
48438	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Number Agreed	6	6	Date Agreed	01/02/2020	3	03/05/2020	3	Recruitment Finished
48439	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	Number Agreed	3	3	Date Agreed	31/03/2020	0	12/05/2020	0	Withdrawn By Sponsor

Q2 2020/21 Delivery

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48419	18/LO/0503	239042	Safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in patients with idiopathic pulmonary fibrosis (IPF) on no background anti-fibrotic (Part 1) and safety and tolerability of BI 1015550 on top of Nintedanib and Pir	Number Agreed	1	1	Date Agreed	18/09/2019	1	23/07/2019	1	Recruitment Finished
48420	17/LO/1088	228921	A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation	Number Agreed	3	3	Date Agreed	24/11/2018	5	24/08/2019	5	Recruitment Finished
48421	16/LO/0286	188120	The?CELEB?trial:?Comparative?Effectiveness?of?Lung?volume?reduction?surgery?for?Emphysema?and?Bronchoscopic lung?volume?reduction?with?valve?placement	Range Agreed	30	40	Date Agreed	28/08/2019	30	28/08/2019	30	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48422	19/NW/0026	249432	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	31/08/2019	3	05/09/2019	3	Recruitment Finished
48423	18/LO/0295	238305	An Open-label, non-controlled, multicentre, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection - OPTIMA	Number Agreed	1	1	Date Agreed	25/10/2019	2	25/10/2019	2	Recruitment Finished
48424	16/WS/0223	213242	A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosphodiesterase-5 inhibitors (PDE-5i) with or without en	Number Agreed	2	2	Date Agreed	31/10/2019	1	31/10/2019	1	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48425	18/EE/0092	235968	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and	Number Agreed	6	6	Date Agreed	31/07/2019	8	06/12/2019	8	Recruitment Finished
48426	18/NI/0178	253727	A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation	Number Agreed	2	2	Date Agreed	30/12/2019	0	10/12/2019	0	Withdrawn By Sponsor
48427	18/LO/0967	230460	Clinical Investigation of the VytronUS Ablation System for Treatment	Number Agreed	15	15	Date Agreed	31/12/2019	6	06/09/2019	6	Withdrawn By Sponsor
48428	18/SW/0115	241436	AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS- IMPALA EXTENSION	Number Agreed	4	4	Date Agreed	21/06/2021	4	25/07/2019	4	Withdrawn By Sponsor

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48429	19/NW/0394	264789	CQAW039B2201: A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years with asthma	Number Agreed	1	1	Date Agreed	30/06/2020	0	16/12/2019	0	Withdrawn By Sponsor
48430	17/NW/0678	233267	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectas	Number Agreed	3	3	Date Agreed	31/12/2019	0	31/12/2019	0	Withdrawn By Sponsor
48431	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and	Number Agreed	3	3	Date Agreed	01/03/2020	4	01/03/2020	4	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
48432	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/- intervention on outcomes in patients with non ST-elevation myocardial infarction	Number Agreed	25	25	Date Agreed	30/09/2020	0	19/03/2020	0	Withdrawn By Host
48437	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	31/01/2020	3	31/03/2020	3	Recruitment Finished
48438	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Number Agreed	6	6	Date Agreed	01/02/2020	3	03/05/2020	3	Recruitment Finished
48439	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	Number Agreed	3	3	Date Agreed	31/03/2020	0	12/05/2020	0	Withdrawn By Sponsor